NCT06471361

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants With Generalized Myasthenia Gravis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.

Conditions

• Generalized Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	Zilucoplan	Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

Timeline

• Start date: 2024-08-27
• Primary completion: 2025-01-28
• Completion: 2025-02-03
• First posted: 2024-06-24
• Last updated: 2026-03-27
• Results posted: 2026-03-27

Locations

11 sites across 3 countries: United States, Poland, United Kingdom

Regulatory

• FDA-regulated drug study